Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Pyxis Oncology Inc (NASDAQ: PYXS) closed the day trading at $1.35 up 2.27% from the previous closing price of $1.32. In other words, the price has increased by $2.27 from its previous closing price. On the day, 0.79 million shares were traded.
Ratios:
For a better understanding of PYXS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.33 and its Current Ratio is at 7.33. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
On November 08, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $13.
On August 08, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $10.Stifel initiated its Buy rating on August 08, 2024, with a $10 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 26 ’24 when Connealy Pamela Ann bought 88,850 shares for $1.96 per share. The transaction valued at 174,364 led to the insider holds 1,199,143 shares of the business.
Stock Price History:
Over the past 52 weeks, PYXS has reached a high of $6.85, while it has fallen to a 52-week low of $1.23. The 50-Day Moving Average of the stock is -13.38%, while the 200-Day Moving Average is calculated to be -56.01%.
Shares Statistics:
A total of 59.45M shares are outstanding, with a floating share count of 42.25M. Insiders hold about 28.95% of the company’s shares, while institutions hold 40.70% stake in the company.
Earnings Estimates
At present, 7.0 analysts are actively evaluating the performance of Pyxis Oncology Inc (PYXS) in the stock market.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.29 and low estimates of -$0.38.
Analysts are recommending an EPS of between -$1.0 and -$1.38 for the fiscal current year, implying an average EPS of -$1.09. EPS for the following year is -$1.31, with 7.0 analysts recommending between -$1.04 and -$1.46.
